ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

DOW JONES NEWSWIRES Endo Pharmaceuticals Holdings Inc.'s (ENDP) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition. Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late. First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply. Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant. Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million. Gross margin fell to 47.2% from 58.7%. Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%. Overall branded drug sales were down 3% while generics sales increased 8%. Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Novartis (NVS)
10/25/201604:40:00Novartis Profit Helped by GlaxoSmithKline Joint Venture
10/25/201603:53:00Novartis Profit Helped by GlaxoSmithKline Joint Venture -- Update
10/25/201602:01:00Novartis Net Income Rose in 3rd Quarter
10/21/201608:14:00Novartis AG 3Q 2016 - Forecast
10/05/201608:20:00Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/02/201623:40:00Novo Nordisk Bets on Riskier Insulin Research
09/23/201613:11:00Novartis receives three new FDA approvals for the expanded use...
08/30/201618:50:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30/201618:31:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/22/201608:50:00Eli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/15/201610:20:00Stada Arzneimittel Braced for Investor Battle
08/05/201614:50:00AbbVie Sues Amgen Over Humira
07/27/201617:10:00Amgen Profit Rises 13%, 2016 Outlook Raised
07/26/201608:00:00Eli Lilly Revenue Rise Helped by New Products
07/25/201616:10:00Stada Arzneimittel Feels More Heat From Active Ownership
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20/201603:05:00Business Watch -- WSJ
07/19/201619:00:00ADRs End Lower; Ericsson Falls
07/19/201604:36:00Novartis Warns on Profit as It Boosts Investment in Heart-Failure...
07/19/201603:40:00Novartis Warns on Profit as Entresto Investment Weighs

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations